IP Library Granted Patent US 10,137,091
Granted Patent B2
US 10,137,091 · App. 13/582,940 · Granted Nov 27, 2018

Immediate/delayed drug delivery

Inventors: Alexander Mullen (Glasgow, GB); Howard Stevens (Glasgow, GB); Sarah Eccleston (Glasgow, GB)
Assignee: UNIVERSITY OF STRATHCLYDE
A61K9/2054A61K9/209A61K9/2018A61K9/2068A61K31/00A61K31/196A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,091
App. No.
13/582,940
Granted
Nov 27, 2018
Kind
B2
Abstract

In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and while a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.

Claims (21)

1. A press-coated tablet formulation for an immediate, followed by a delayed release of an active agent, the tablet comprising:

(a) a core comprising an active agent together with an excipient(s); and

(b) a delayed release layer surrounding the core and comprising a wax and a low substituted hydroxypropyl cellulose in a ratio of 40:60 to 60:40 w/w; wherein the delayed release layer substantially delays release of the active agent within the core for between 3-8 hours after administration of the tablet to a subject and thereafter a pulsed release of the active agent from the core occurs, such that at least 70% of the active agent in the core is released within 5-45 minutes and wherein the low substituted hydroxypropyl cellulose is micronized with a mean particle diameter of 20 mm and has a molecular weight of 115,000 and a hydroxypropyl cellulose content of 8%; and

(c) a top-coating layer comprising a portion of an active agent together with one or more excipients wherein a substantially immediate pulsed release of the active agent occurs following administration to the subject of the tablet;

wherein the active agent in the core and on the top-coating layer is an NSAID.

2. The press-coated tablet according to claim 1 further comprising an amount of an active agent, which is the same or different to the active agent in the core and/or top-coating layer, in the delayed release layer.

3. The press-coated tablet according to claim 1 wherein the wax is selected from the group consisting of beeswax, carnuba wax, microcrystalline wax, hydrogenated castor oil, and a glyceryl ester.

4. The press-coated tablet according to claim 3 wherein the glyceryl ester is glycerol behenate.

5. The press-coated tablet according to claim 1 wherein the wax and the low substituted hydroxypropyl cellulose are present in a ratio of 45:55 to 55:45 w/w.

6. The press-coated tablet according to claim 5 wherein the wax and the low substituted hydroxypropyl cellulose are present in a ratio of 50:50 w/w ratio and wherein the wax is glycerol behenate.

7. A method of alleviating pain and/or inflammation, the method comprising administering a press-coated tablet according to claim 1 .

8. The method according to claim 7 wherein the NSAID is diclofenac.

9. The method according to claim 7 wherein delayed release of the NSAID is achieved by providing a press-coated tablet comprising a delayed release layer surrounding a core comprising the NSAID agent.

10. The method according to claim 9 wherein the delayed release layer comprises a wax and a low substituted hydroxypropyl cellulose, wherein the low substituted hydroxpropyl cellulose is micronized with a mean particle diameter of 20 mm and has a molecular weight of 115,000 and a hydroxypropyl cellulose content of 8%.

11. The press-coated tablet according to claim 1 , wherein the active agent is diclofenac.

12. A press-coated tablet formulation for an immediate, followed by a delayed release of an NSAID active agent, the tablet comprising:

(a) a core comprising an active agent together with an excipient(s); and

(b) a delayed release layer surrounding the core and comprising a wax and a low substituted hydroxypropyl cellulose in a ratio of 40:60 to 60:40 w/w; wherein the delayed release layer substantially delays release of the active agent within the core for between 3-8 hours, and thereafter a pulsed release of the active agent from the core occurs, such that at least 70% of the active agent in the core is released within 5-45 minutes; wherein the low substituted hydroxypropyl cellulose is micronized with a mean particle diameter of 20 mm and has a molecular weight of 115,000 and a hydroxypropyl cellulose content of 8%; and

(c) a top-coating layer comprising a portion of an active agent together with one or more excipients wherein a substantially immediate pulsed release of the active agent occurs following administration to the subject of the tablet; wherein said release is measured in 900 ml of 0.01M sodium phosphate buffer at pH 7, at 37° C. as determined by UV analysis at 248 nm;

wherein the active agent in the core and on the top-coating layer is an NSAID.

13. The press-coated tablet according to claim 12 further comprising an amount of an active agent, which is the same or different to the active agent in the core and/or top-coating layer, in the delayed release layer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: THE UNIVERSITY OF STRATHCLYDE
To: DRUG DELIVERY INTERNATIONAL LIMITED
Reel/Frame 050055/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2012
From: MULLEN, ALEXANDER; STEVENS, HOWARD; ECCLESTON, SARAH
To: UNIVERSITY OF STRATHCLYDE
Reel/Frame 029060/0700 →
Priority Claims (1)
GB 1003731.5 · Mar 5, 2010 · national
Continuity (1)
Related Publication 20130017262A1 · Jan 17, 2013
Cited By (4)
US 12,246,023 US 12,447,155 US 12,565,478 US 12,616,702